



## Abiomed Fourth Quarter Fiscal 2020 Earnings and Conference Call Notification

April 10, 2020

DANVERS, Mass.--(BUSINESS WIRE)--Apr. 10, 2020-- [Abiomed, Inc.](#) (NASDAQ: ABMD) announced that on Thursday, April 30, 2020, the Company will release financial results for the fourth quarter of fiscal 2020. The Company will host a conference call to discuss the results on Thursday, April 30, 2020, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call.

To listen to the call live, please tune into the webcast via <https://edge.media-server.com/mmc/p/gfyn6zsu> or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11:00 a.m. ET April 30, 2020 through 11:00 a.m. ET on May 7, 2020. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 7361069.

### ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: [www.abiomed.com](http://www.abiomed.com).

### FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200410005021/en/): <https://www.businesswire.com/news/home/20200410005021/en/>

Todd Trapp  
Vice President and Chief Financial Officer  
978-646-1680  
[ttrapp@abiomed.com](mailto:ttrapp@abiomed.com)

Source: Abiomed, Inc.